Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.40−0.05 (-10.74%)
Close on Nov 17, 2026Market cap $110.95MP/E –Yield –
Akebia Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Akebia Therapeutics's price to sales ratio was 0.7× on Nov 11, 2026, against 1.9× a year earlier. Over the last 5 years it ranged from 0.2× to 5.2×, with a median of 1.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.7× | −1.2 |
| 2025 | Dec 31, 2025 | 1.9× | −0.5 |
| 2024 | Dec 31, 2024 | 2.4× | +1.2 |
| 2023 | Dec 29, 2023 | 1.2× | +0.8 |
| 2022 | Dec 30, 2022 | 0.4× | −1.5 |
| 2021 | Dec 31, 2021 | 1.9× | +0.6 |
| 2020 | Dec 31, 2020 | 1.3× | −1.0 |
| 2019 | Dec 31, 2019 | 2.3× | +1.0 |
| 2018 | Dec 31, 2018 | 1.3× | −330.2 |
| 2017 | Apr 28, 2017 | 331.6× | – |
See a number that looks wrong?